ADMS Adamas Pharmaceuticals Inc

Price (delayed)

$5.38

Market cap

$244.3M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.79

Enterprise value

$255.17M

Highlights
The equity has soared by 137% YoY and by 112% from the previous quarter
The company's EPS rose by 46% YoY and by 12% QoQ
ADMS's quick ratio has soared by 79% QoQ but it is down by 8% YoY

Key stats

What are the main financial stats of ADMS
Market
Shares outstanding
45.41M
Market cap
$244.3M
Enterprise value
$255.17M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
27.7
Price to sales (P/S)
2.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.22
Earnings
Revenue
$79.29M
EBIT
-$39.53M
EBITDA
-$38.78M
Free cash flow
-$54.46M
Per share
EPS
-$1.79
Free cash flow per share
-$1.55
Book value per share
$0.19
Revenue per share
$2.25
TBVPS
$4.79
Balance sheet
Total assets
$169.25M
Total liabilities
$163.31M
Debt
$135.7M
Equity
$5.94M
Working capital
$128.93M
Liquidity
Debt to equity
22.86
Current ratio
5.42
Quick ratio
4.7
Net debt/EBITDA
-0.28
Margins
EBITDA margin
-48.9%
Gross margin
97.7%
Net margin
-67.3%
Operating margin
-51.2%
Efficiency
Return on assets
-38.4%
Return on equity
N/A
Return on invested capital
-22.4%
Return on capital employed
-28.2%
Return on sales
-49.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADMS stock price

How has the Adamas Pharmaceuticals stock price performed over time
Intraday
3.66%
1 week
5.7%
1 month
5.49%
1 year
102.26%
YTD
24.25%
QTD
12.08%

Financial performance

How have Adamas Pharmaceuticals's revenue and profit performed over time
Revenue
$79.29M
Gross profit
$77.44M
Operating income
-$40.58M
Net income
-$53.33M
Gross margin
97.7%
Net margin
-67.3%
The operating margin has soared by 63% YoY and by 14% from the previous quarter
ADMS's net margin has soared by 58% YoY and by 13% QoQ
ADMS's operating income is up by 48% year-on-year and by 8% since the previous quarter
Adamas Pharmaceuticals's net income has increased by 42% YoY and by 7% QoQ

Growth

What is Adamas Pharmaceuticals's growth rate over time

Valuation

What is Adamas Pharmaceuticals stock price valuation
P/E
N/A
P/B
27.7
P/S
2.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.22
The company's EPS rose by 46% YoY and by 12% QoQ
The equity has soared by 137% YoY and by 112% from the previous quarter
The stock's price to sales (P/S) is 100% less than its 5-year quarterly average of 898.3 but 49% more than its last 4 quarters average of 1.6
Adamas Pharmaceuticals's revenue has increased by 38% YoY and by 6% QoQ

Efficiency

How efficient is Adamas Pharmaceuticals business performance
The company's return on sales has surged by 63% YoY and by 14% QoQ
Adamas Pharmaceuticals's return on invested capital has increased by 36% YoY
The return on assets is up by 28% year-on-year and by 11% since the previous quarter

Dividends

What is ADMS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADMS.

Financial health

How did Adamas Pharmaceuticals financials performed over time
ADMS's total assets is 3.6% more than its total liabilities
ADMS's quick ratio has soared by 79% QoQ but it is down by 8% YoY
Adamas Pharmaceuticals's current ratio has surged by 69% QoQ but it has decreased by 3.4% YoY
The equity has soared by 137% YoY and by 112% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.